Abstract
Pharmacokinetics and safety of a hydroxy-beta-propyl solution of itraconazole were assessed in 16 patients in an intensive care unit. On the first 2 days, four 1-h infusions of 200 mg were given at 0, 8, 24, and 32 h. From day 3 to 7, inclusive, a single 1-h infusion of 200 mg of itraconazole was given daily. The intravenous (i.v.) treatment was directly followed by repeated administrations of an oral solution of itraconazole at a dosage of either 200 mg once daily or 200 mg twice daily (b.i.d.). During i.v. treatment, steady-state concentrations of itraconazole and hydroxy-itraconazole in plasma were reached within 48 and 96 h, respectively. At the end of i.v. treatment, mean (+/- standard deviation) itraconazole and hydroxy-itraconazole trough concentrations in plasma were 0.344 +/- 0.140 and 0.605 +/- 0.205 microg/ml, respectively. After the 2-week oral follow-up of 200 mg once daily the mean trough concentration had decreased to 0.245 microg/ml, whereas after 200 mg b.i.d. it increased to 0.369 microg/ml. Diarrhea during oral treatment appeared to be dose related and may be due to the solvent hydroxypropyl-beta-cyclodextrin. More severe laboratory abnormalities were noted during the i.v. than the oral treatment phase, probably related to more severe illness in that period of intensive care, but none proved clinically important. These results suggest that plasma itraconazole levels above 0.250 microg/ml may be achieved and maintained with the 1-week i.v. schedule followed by b.i.d. oral administration, whereas the once-daily oral follow-up seems to be a suboptimal treatment.
Full Text
The Full Text of this article is available as a PDF (150.7 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Beckhouse M. J., Whyte I. M., Byth P. L., Napier J. C., Smith A. J. Altered aminoglycoside pharmacokinetics in the critically ill. Anaesth Intensive Care. 1988 Nov;16(4):418–422. doi: 10.1177/0310057X8801600406. [DOI] [PubMed] [Google Scholar]
- Boucher B. A., Kuhl D. A., Hickerson W. L. Pharmacokinetics of systemically administered antibiotics in patients with thermal injury. Clin Infect Dis. 1992 Feb;14(2):458–463. doi: 10.1093/clinids/14.2.458. [DOI] [PubMed] [Google Scholar]
- Espinel-Ingroff A., Shadomy S., Gebhart R. J. In vitro studies with R 51,211 (itraconazole). Antimicrob Agents Chemother. 1984 Jul;26(1):5–9. doi: 10.1128/aac.26.1.5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Grant S. M., Clissold S. P. Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs. 1989 Mar;37(3):310–344. doi: 10.2165/00003495-198937030-00003. [DOI] [PubMed] [Google Scholar]
- Hardin T. C., Graybill J. R., Fetchick R., Woestenborghs R., Rinaldi M. G., Kuhn J. G. Pharmacokinetics of itraconazole following oral administration to normal volunteers. Antimicrob Agents Chemother. 1988 Sep;32(9):1310–1313. doi: 10.1128/aac.32.9.1310. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Heykants J., Van Peer A., Van de Velde V., Van Rooy P., Meuldermans W., Lavrijsen K., Woestenborghs R., Van Cutsem J., Cauwenbergh G. The clinical pharmacokinetics of itraconazole: an overview. Mycoses. 1989;32 (Suppl 1):67–87. doi: 10.1111/j.1439-0507.1989.tb02296.x. [DOI] [PubMed] [Google Scholar]
- Miyazaki H. M., Kohno S., Miyazaki Y., Mitsutake K., Tomono K., Kaku M., Koga H., Hara K. Efficacy of intravenous itraconazole against experimental pulmonary aspergillosis. Antimicrob Agents Chemother. 1993 Dec;37(12):2762–2765. doi: 10.1128/aac.37.12.2762. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Reed R. L., 2nd, Wu A. H., Miller-Crotchett P., Crotchett J., Fischer R. P. Pharmacokinetic monitoring of nephrotoxic antibiotics in surgical intensive care patients. J Trauma. 1989 Nov;29(11):1462–1470. doi: 10.1097/00005373-198911000-00002. [DOI] [PubMed] [Google Scholar]
- Zaske D. E., Cipolle R. J., Strate R. J. Gentamicin dosage requirements: wide interpatient variations in 242 surgery patients with normal renal function. Surgery. 1980 Feb;87(2):164–169. [PubMed] [Google Scholar]